首页> 外文期刊>Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract >Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review.
【24h】

Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review.

机译:扩大胰十二指肠切除术与血管切除术治疗胰腺癌:系统评价。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVES: This systematic review objectively evaluates the safety and outcomes of extended pancreaticoduodenectomy with vascular resection for pancreatic cancer involving critical adjacent vessels namely the superior mesenteric-portal veins, hepatic artery, superior mesenteric artery, and celiac axis. METHODS: Electronic searches were performed on two databases from January 1995 to August 2009. The end points were: firstly, to evaluate the safety through reporting the mortality rate and associated complications and, secondly, the outcome by reporting the survival after surgery. This was synthesized through a narrative review with full tabulation of results of all included studies. RESULTS: Twenty-eight retrospective studies comprising of 1,458 patients were reviewed. Vein thrombosis and arterial involvement were reported as contraindications to surgery in 62% and 71% of studies, respectively. The median mortality rate was 4% (range, 0% to 17%). The median R0 and R1 rates were 75% (range, 14% to 100%) and 25% (range, 0% to 86%), respectively. In high volume centers, the median survival was 15 months (range, 9 to 23 months). Nine of 10 (90%) studies comparing the survival after extended pancreaticoduodenectomy with vascular resection versus standard pancreaticoduodenectomy reported statistically similar (p > 0.05) survival outcomes. Undertaking vascular resection was not associated with a poorer survival. CONCLUSIONS: The morbidity, mortality, and survival outcome after undertaking extended pancreaticoduodenectomy with vascular resection for pancreatic cancer with venous involvement and/or limited arterial involvement is acceptable in the setting of an expert referral center and should not be a contraindication to a curative surgery.
机译:目的:本系统评价客观地评估了行胰十二指肠切除术联合血管切除术治疗胰腺癌的危险性和结果,胰腺癌涉及关键的相邻血管,即肠系膜上-门静脉,肝动脉,肠系膜上动脉和腹腔轴。方法:从1995年1月至2009年8月在两个数据库中进行电子搜索。终点是:首先,通过报告死亡率和相关并发症来评估安全性;其次,通过报告手术后的生存率来评估结果。这是通过叙述性综述综合而成的,其中包括所有纳入研究的结果。结果:回顾性研究包括1458名患者的28个回顾性研究。据报道,分别有62%和71%的研究表明静脉血栓形成和动脉受累是手术的禁忌症。中位死亡率为4%(范围为0%至17%)。中位数R0和R1比率分别为75%(范围为14%至100%)和25%(范围为0%至86%)。在高容量中心,中位生存期为15个月(9到23个月不等)。 10项研究(90%)中有9项比较了扩大的胰十二指肠切除术与标准的血管十二指肠切除术相比的生存率,统计学上相似(p> 0.05)。进行血管切除术并不伴有较差的生存率。结论:对于有静脉累及和/或动脉受限的胰腺癌,行扩大的胰十二指肠切除术并进行血管切除术后,其发病率,死亡率和生存结果在专家转诊中心是可以接受的,不应作为治愈性手术的禁忌证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号